{
    "id": 25920,
    "fullName": "BCAN - NTRK1",
    "impact": "fusion",
    "proteinEffect": "gain of function - predicted",
    "geneVariantDescriptions": [
        {
            "description": "BCAN-NTRK1 results from the fusion of BCAN and NTRK1, and has not been biochemically characterized, but leads to transformation of p53-null cells in culture and tumor formation in mouse models (PMID: 24647444, PMID: 29532792), and therefore, is predicted to result in a gain of function. BCAN-NTRK1 has been identified in glioblastoma multiforme (PMID: 24647444).",
            "references": [
                {
                    "id": 7533,
                    "pubMedId": 24647444,
                    "title": "NTRK1 fusion in glioblastoma multiforme.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/24647444"
                },
                {
                    "id": 285,
                    "pubMedId": null,
                    "title": null,
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed"
                },
                {
                    "id": 14730,
                    "pubMedId": 29532792,
                    "title": "Author Correction: Somatic chromosomal engineering identifies BCAN-NTRK1 as a potent glioma driver and therapeutic target.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29532792"
                }
            ]
        }
    ],
    "type": null,
    "gene": {
        "id": 63827,
        "geneSymbol": "BCAN",
        "terms": [
            "BCAN",
            "BEHAB",
            "CSPG7"
        ]
    },
    "variant": "BCAN - NTRK1",
    "createDate": "01/12/2017",
    "updateDate": "04/10/2019",
    "referenceTranscriptCoordinates": null,
    "partnerGenes": [
        {
            "gene": {
                "id": 4914,
                "geneSymbol": "NTRK1",
                "terms": [
                    "NTRK1",
                    "MTC",
                    "p140-TrkA",
                    "TRK",
                    "Trk-A",
                    "TRK1",
                    "TRKA"
                ]
            }
        }
    ],
    "evidence": [
        {
            "id": 10490,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase I trial, treatment with Rozlytrek (entrectinib) resulted in stable disease and 60% reduction of tumor burden in a patient with glioneuronal tumor harboring BCAN-NTRK1 fusion (PMID: 28183697).",
            "molecularProfile": {
                "id": 27053,
                "profileName": "BCAN - NTRK1"
            },
            "therapy": {
                "id": 1455,
                "therapyName": "Entrectinib",
                "synonyms": null
            },
            "indication": {
                "id": 3620,
                "name": "central nervous system cancer",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 8566,
                    "pubMedId": 28183697,
                    "title": "Safety and Antitumor Activity of the Multitargeted Pan-TRK, ROS1, and ALK Inhibitor Entrectinib: Combined Results from Two Phase I Trials (ALKA-372-001 and STARTRK-1).",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28183697"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 16312,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Rozlytrek (entrectinib) treatment reduced viability of TP53-null mouse adult neuronal stem cells harboring BCAN-NTRK1 in culture, and improved survival and decreased tumor cell proliferation in xenograft models (PMID: 28695888).",
            "molecularProfile": {
                "id": 31590,
                "profileName": "BCAN - NTRK1 TP53 del"
            },
            "therapy": {
                "id": 1455,
                "therapyName": "Entrectinib",
                "synonyms": null
            },
            "indication": {
                "id": 3620,
                "name": "central nervous system cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 14433,
                    "pubMedId": 28695888,
                    "title": "Somatic chromosomal engineering identifies BCAN-NTRK1 as a potent glioma driver and therapeutic target.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28695888"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        }
    ],
    "molecularProfiles": [
        {
            "id": 27053,
            "profileName": "BCAN - NTRK1",
            "profileTreatmentApproaches": [
                {
                    "id": 19332,
                    "name": "Larotrectinib",
                    "profileName": "BCAN - NTRK1"
                }
            ]
        },
        {
            "id": 31590,
            "profileName": "BCAN - NTRK1 TP53 del",
            "profileTreatmentApproaches": [
                
            ]
        }
    ],
    "allTranscriptCoordinates": [
        
    ]
}